LONDON (Alliance News) - ValiRx PLC said Thursday that it had been granted a patent in Japan for its cancer screening test gene biomarker NAV3.
The biomarker was acquired by the company's subsidiary ValiFinn Oy in 2012.
As a result, ValiRx now has patent protection on this biomarker in Japan, Europe, and Australia, with further patents pending in the US and other territories.
Shares in ValiRx were trading down 0.4% at 0.274 pence Thursday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.